Preliminary Data from a Phase 1/2 Study of a Gene Therapy for X-Linked Retinitis Pigmentosa has been Shared
Free-Photos / Pixabay

Preliminary Data from a Phase 1/2 Study of a Gene Therapy for X-Linked Retinitis Pigmentosa has been Shared

Nightstar Therapeutics has released preliminary data from a Phase 1/2 study of an experimental gene therapy designed to treat X-linked retinitis pigmentosa. For more detailed information you can view the…

Continue Reading Preliminary Data from a Phase 1/2 Study of a Gene Therapy for X-Linked Retinitis Pigmentosa has been Shared